NICE says yes to Servier's Procoralan, but only after other treatments
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has published draft guidance adding Servier's Procoralan (ivabradine) to the list of treatments available for patients with chronic heart failure. The draft guidance is largely in line with 2012 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure and, according to NICE, it reflects the "robust" evidence supporting existing treatments.